TY - STD TI - Antiretroviral drugs used in the treatment of HIV infection. US Food and Drug Administration. http://www.fda.gov/forpatients/illness/hivaids/treatment/ucm118915.htm. UR - http://www.fda.gov/forpatients/illness/hivaids/treatment/ucm118915.htm ID - ref1 ER - TY - JOUR AU - Tang, M. W. AU - Shafer, R. W. PY - 2012 DA - 2012// TI - HIV-1 antiretroviral resistance scientific principles and clinical applications JO - Drugs VL - 72 UR - https://doi.org/10.2165/11633630-000000000-00000 DO - 10.2165/11633630-000000000-00000 ID - Tang2012 ER - TY - JOUR AU - Sung, H. AU - Foley, B. T. AU - Bae, I. G. AU - Chi, H. S. AU - Cho, Y. K. PY - 2001 DA - 2001// TI - Phylogenetic analysis of reverse transcriptase in antiretroviral drug-naïve Korean HIV type 1 patients JO - AIDS Res Hum Retroviruses VL - 17 UR - https://doi.org/10.1089/08892220152644250 DO - 10.1089/08892220152644250 ID - Sung2001 ER - TY - JOUR AU - Sung, H. AU - Foley, B. T. AU - Ahn, S. H. AU - Kim, Y. B. AU - Chae, J. D. AU - Shin, Y. O. PY - 2003 DA - 2003// TI - Natural polymorphisms of protease in protease inhibitor-naive HIV-1 infected patients in Korea: a novel L63M in subtype B JO - AIDS Res Hum Retroviruses VL - 19 UR - https://doi.org/10.1089/088922203766774586 DO - 10.1089/088922203766774586 ID - Sung2003 ER - TY - JOUR AU - Paredes, R. AU - Clotet, B. PY - 2010 DA - 2010// TI - Clinical management of HIV-1 resistance JO - Antiviral Res VL - 85 UR - https://doi.org/10.1016/j.antiviral.2009.09.015 DO - 10.1016/j.antiviral.2009.09.015 ID - Paredes2010 ER - TY - JOUR AU - Johnson, V. A. AU - Calvez, V. AU - Gunthard, H. F. AU - Paredes, R. AU - Pillay, D. AU - Shafer, R. W. PY - 2013 DA - 2013// TI - Update of the drug resistance mutations in HIV-1: March 2013 JO - Top Antivir Med VL - 21 ID - Johnson2013 ER - TY - JOUR AU - Melikian, G. L. AU - Rhee, S. Y. AU - Varghese, V. AU - Porter, D. AU - White, K. AU - Taylor, J. PY - 2014 DA - 2014// TI - Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing JO - J Antimicrob Chemother VL - 69 UR - https://doi.org/10.1093/jac/dkt316 DO - 10.1093/jac/dkt316 ID - Melikian2014 ER - TY - JOUR AU - Elsayed, R. K. AU - Caldwell, D. J. PY - 2010 DA - 2010// TI - Etravirine: a novel nonnucleoside reverse transcriptase inhibitor for managing human immunodeficiency virus infection JO - Am J Health Syst Pharm VL - 67 UR - https://doi.org/10.2146/ajhp080559 DO - 10.2146/ajhp080559 ID - Elsayed2010 ER - TY - JOUR AU - Towner, W. J. AU - Cassetti, I. AU - Domingo, P. AU - Nijs, S. AU - Kakuda, T. N. AU - Vingerhoets, J. PY - 2010 DA - 2010// TI - Etravirine: clinical review of a treatment option for HIV type-1-infected patients with non-nucleoside reverse transcriptase inhibitor resistance JO - Antivir Ther VL - 15 UR - https://doi.org/10.3851/IMP1651 DO - 10.3851/IMP1651 ID - Towner2010 ER - TY - JOUR AU - Sterrantino, G. AU - Zaccarelli, M. AU - Colao, G. AU - Baldanti, F. AU - Giambenedetto, S. AU - Carli, T. PY - 2012 DA - 2012// TI - Genotypic resistance profiles associated with virological failure to darunavir-containing regimens: a cross-sectional analysis JO - Infection VL - 40 UR - https://doi.org/10.1007/s15010-011-0237-y DO - 10.1007/s15010-011-0237-y ID - Sterrantino2012 ER - TY - JOUR AU - Talbot, A. AU - Grant, P. AU - Taylor, J. AU - Baril, J. G. AU - Liu, T. F. AU - Charest, H. PY - 2010 DA - 2010// TI - Predicting tipranavir and darunavir resistance using genotypic, phenotypic, and virtual phenotypic resistance patterns: an independent cohort analysis of clinical isolates highly resistant to all other protease inhibitors JO - Antimicrob Agents Chemother VL - 54 UR - https://doi.org/10.1128/AAC.00096-10 DO - 10.1128/AAC.00096-10 ID - Talbot2010 ER - TY - JOUR AU - Bethune, M. P. PY - 2010 DA - 2010// TI - Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989–2009) JO - Antiviral Res VL - 85 UR - https://doi.org/10.1016/j.antiviral.2009.09.008 DO - 10.1016/j.antiviral.2009.09.008 ID - Bethune2010 ER - TY - JOUR AU - Peeters, M. AU - Vingerhoets, J. AU - Tambuyzer, L. AU - Azijn, H. AU - Hill, A. AU - Meyer, S. PY - 2010 DA - 2010// TI - Etravirine limits the emergence of darunavir and other protease inhibitor resistance-associated mutations in the DUET trials JO - AIDS VL - 24 UR - https://doi.org/10.1097/QAD.0b013e328336ac2a DO - 10.1097/QAD.0b013e328336ac2a ID - Peeters2010 ER - TY - JOUR AU - Wensing, A. M. AU - Maarseveen, N. M. AU - Nijhuis, M. PY - 2010 DA - 2010// TI - Fifteen years of HIV protease inhibitors: raising the barrier to resistance JO - Antiviral Res VL - 85 UR - https://doi.org/10.1016/j.antiviral.2009.10.003 DO - 10.1016/j.antiviral.2009.10.003 ID - Wensing2010 ER - TY - JOUR AU - Dierynck, I. AU - Meyer, S. AU - Lathouwers, E. AU - Vanden Abeele, C. AU - Casteele, T. AU - Spinosa-Guzman, S. PY - 2010 DA - 2010// TI - In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naïve patients JO - Antivir Ther VL - 15 UR - https://doi.org/10.3851/IMP1697 DO - 10.3851/IMP1697 ID - Dierynck2010 ER - TY - JOUR AU - Barrail-Tran, A. AU - Yazdanpanah, Y. AU - Goldwirt, L. AU - Chene, G. AU - Colin, C. AU - Piketty, C. PY - 2010 DA - 2010// TI - Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment-experienced patients JO - AIDS VL - 24 UR - https://doi.org/10.1097/QAD.0b013e32833d89fa DO - 10.1097/QAD.0b013e32833d89fa ID - Barrail-Tran2010 ER - TY - JOUR AU - Xu, H. T. AU - Oliveira, M. AU - Asahchop, E. L. AU - McCallum, M. AU - Quashie, P. K. AU - Han, Y. PY - 2012 DA - 2012// TI - Molecular mechanism of antagonism between the Y181C and E138K mutations in HIV-1 reverse transcriptase JO - J Virol VL - 86 UR - https://doi.org/10.1128/JVI.02005-12 DO - 10.1128/JVI.02005-12 ID - Xu2012 ER - TY - JOUR AU - Zhang, H. AU - Zhou, Y. AU - Alcock, C. AU - Kiefer, T. AU - Monie, D. AU - Siliciano, J. PY - 2004 DA - 2004// TI - Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1 JO - J Virol VL - 78 UR - https://doi.org/10.1128/JVI.78.4.1718-1729.2004 DO - 10.1128/JVI.78.4.1718-1729.2004 ID - Zhang2004 ER - TY - JOUR AU - Choi, J. Y. AU - Kwon, O. K. AU - Choi, S. Y. AU - Park, Y. K. AU - Kim, S. S. PY - 2011 DA - 2011// TI - Drug susceptibility of human immunodeficiency virus type 1-derived pseudoviruses from treatment-experienced patients to protease inhibitors and reverse transcriptase inhibitors, using a modified single-round assay JO - J Clin Virol VL - 50 UR - https://doi.org/10.1016/j.jcv.2010.09.012 DO - 10.1016/j.jcv.2010.09.012 ID - Choi2011 ER -